Glaukos Corporation (NYSE:GKOS) Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Glaukos Corporation by 8.3% in the first quarter, holding 89,324 shares valued at approximately $8.79 million.
• Analysts have set new target prices for Glaukos, with Truist Financial maintaining a "buy" rating and a target price of $135.00, while Morgan Stanley lowered their target to $72.00.
• Glaukos reported a revenue of $106.66 million for the last quarter, up 24.6% year-over-year, beating analyst expectations and improving from a previous earnings per share of ($0.70) to ($0.22).

Universal Beteiligungs und Servicegesellschaft mbH lifted its position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 8.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 89,324 shares of the medical instruments supplier's stock after acquiring an additional 6,847 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.16% of Glaukos worth $8,791,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in GKOS. Bessemer Group Inc. raised its position in shares of Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 158 shares in the last quarter. Whipplewood Advisors LLC raised its position in shares of Glaukos by 3,957.1% during the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 277 shares in the last quarter. First Horizon Advisors Inc. raised its position in shares of Glaukos by 72.9% during the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after acquiring an additional 159 shares in the last quarter. Versant Capital Management Inc raised its position in shares of Glaukos by 583.9% during the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after acquiring an additional 327 shares in the last quarter. Finally, CoreCap Advisors LLC raised its position in shares of Glaukos by 36.4% during the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after acquiring an additional 200 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Price Performance

Shares of Glaukos stock traded down $0.76 during trading on Tuesday, hitting $94.16. The stock had a trading volume of 273,191 shares, compared to its average volume of 911,633. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.49 and a quick ratio of 5.62. The firm has a market cap of $5.38 billion, a P/E ratio of -39.76 and a beta of 0.82. The business has a fifty day moving average of $98.51 and a two-hundred day moving average of $109.60. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. The business had revenue of $106.66 million during the quarter, compared to analyst estimates of $102.78 million. Glaukos had a negative return on equity of 10.66% and a negative net margin of 31.40%. The company's revenue was up 24.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.70) earnings per share. On average, sell-side analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on GKOS shares. Stifel Nicolaus lowered their price objective on Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Mizuho lowered their price objective on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research note on Wednesday, April 16th. Needham & Company LLC lowered their price objective on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Truist Financial restated a "buy" rating and set a $135.00 price objective (down from $140.00) on shares of Glaukos in a research note on Thursday, May 1st. Finally, Piper Sandler lowered their price objective on Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research note on Tuesday, April 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, Glaukos presently has a consensus rating of "Moderate Buy" and an average price target of $134.67.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.